Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- AZ, BMKK Aim to Develop Market for Bydureon as Drug before Insulin
June 20, 2013
- Anatomy of Mutual Reliance - Diovan Papers and Company Part 1: A Blurred Line
June 20, 2013
- Takeda’s 3 Nesina Family Drugs Make US Debut
June 19, 2013
- MSD to Continue Efforts for HPV Vaccine Recommendation
June 19, 2013
- Novartis Pharma to Voluntarily Refrain from Participation in JPMA’s Board of Directors Meeting
June 19, 2013
- Chairman Kato Resigns, to Move to Specially Appointed Professor Position at University of Tokyo: AZ
June 19, 2013
- GSK Says No Evidence Shows Causal Link between HPV Vaccines and Serious Adverse Events
June 18, 2013
- Shionogi Signs MOU on R&D with Six Universities in Ireland
June 18, 2013
- Eisai to Expand Packaging Facility at UK Plant, Eying Lenvatinib Launch
June 18, 2013
- Takeda, Pfizer Settle Protonix Patent Lawsuit with Teva, Sun for US$2.15 Billion
June 17, 2013
- Stroke Prevention Effects Confirmed in PIII Study of Pradaxa in Asia: BI Japan
June 17, 2013
- Daiichi Sankyo, JICA Start Technical Cooperation on MR Vaccine Production in Vietnam
June 17, 2013
- Sanofi Ends Development on Iniparib, Otamixaban
June 14, 2013
- ARBs Still Best Sellers in FY2012 Sales Ranking, Januvia Ranks in Top 10 after only 3 Years of Launch
June 14, 2013
- Nippon Shinyaku’s Licensee Taejoon Pharm Launches Gaslon N-OD Tablets in South Korea
June 14, 2013
- AbbVie, Meiji Seika Pharma Start PIII of Fluvoxamine for Pediatric OCD
June 14, 2013
- SGLT-2 Inhibitors Being Submitted for Marketing Authorization; First of 6 APIs Should Debut Next Spring
June 14, 2013
- Daiichi Sankyo Launches Osteoporosis Treatment Pralia
June 13, 2013
- Domestic Sales of OTC Drugs Expected to Reach 607.2 Billion Yen in 2013: Fuji-Keizai
June 13, 2013
- DSP, Shionogi Launch Avapro, Irbetan Tablets 200 mg
June 13, 2013
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…